Valeo Financial Advisors LLC Decreases Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Valeo Financial Advisors LLC trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 24.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,624 shares of the medical equipment provider’s stock after selling 4,418 shares during the period. Valeo Financial Advisors LLC’s holdings in Zimmer Biomet were worth $1,471,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of ZBH. Ables Iannone Moore & Associates Inc. purchased a new stake in Zimmer Biomet during the 4th quarter valued at $30,000. Crewe Advisors LLC purchased a new stake in Zimmer Biomet during the 1st quarter valued at $31,000. Bangor Savings Bank purchased a new stake in Zimmer Biomet during the 3rd quarter valued at $31,000. Family Firm Inc. purchased a new stake in Zimmer Biomet during the 2nd quarter valued at $33,000. Finally, J.Safra Asset Management Corp raised its holdings in Zimmer Biomet by 712.1% during the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 235 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $103.50 on Friday. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90. The stock’s 50-day moving average is $108.37 and its 200 day moving average is $113.21. The company has a market cap of $21.29 billion, a P/E ratio of 22.40, a PEG ratio of 1.89 and a beta of 1.02. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 0.63.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.02. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The company had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter last year, the company earned $1.82 earnings per share. The firm’s revenue for the quarter was up 3.9% compared to the same quarter last year. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.93%. The ex-dividend date of this dividend is Monday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Oppenheimer decreased their price target on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Canaccord Genuity Group reduced their target price on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, September 10th. Morgan Stanley reduced their target price on Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, September 17th. Finally, Robert W. Baird reduced their target price on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $124.53.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.